TAAR1 and laryngotracheoesophageal cleft: The difference between the conclusions of the two studies may be that patients with LC who received Tα1 as postoperative adjuvant therapy underwent surgery, and patients with improved treatment efficacy and could receive surgery had an earlier stage of TNM, and the GASTO-1043 study included patients with advanced LC, had a relatively small sample size of 138 patients, and had relatively insufficient postoperative follow-up time, which may have contributed to the failure to achieve a statistically significant difference in OS after the addition of Tα1 to CCRT.